The economic burden of cutaneous malignant melanoma in the Greek outpatient setting during the 3-year period, 2017-2019

OBJECTIVE To quantify direct medical outpatient costs incurred by cutaneous malignant melanoma (CMM) covered by the national health insurance system in Greece, for the period 2017-2019. METHOD This study is a prevalence-based, cost-of-illness study, conducted from the perspective of the third-party insurer in Greece. Using an electronic third-party payer database, examinations conducted on, and pharmaceuticals prescribed to Greek patients diagnosed with CMM were collected and converted to costs using local unit costs. Outpatient healthcare resource utilization (HCRU) data were extracted for CMM-related ICD10 codes. Unit costs were obtained from the pharmaceuticals reimbursement lists of the National Organization for the Provision of Health Services (EOPYY) and state tariffs. RESULTS The total outpatient costs of CMM between 2017 and 2019 amounted to epsilon 74,007,121 更多